title: Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study.
abstract: BACKGROUND
  The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting β2-agonist (LABA) formoterol fumarate (formoterol) are being made available as a combination product (fluticasone/formoterol, flutiform ®) in a single aerosol inhaler. This 12-week, open-label, randomized, active-controlled, parallel-group, multicentre, phase 3 study compared the efficacy and safety of fluticasone/formoterol with the commercially available combination product fluticasone/salmeterol.
  
  
  METHODS
  Patients aged ≥ 18 years (N = 202) with mild-to-moderate-severe, persistent asthma for ≥ 6 months prior to screening were included in the study. After a screening phase (4-10 days), eligible patients were randomized 1:1 to receive fluticasone/formoterol or fluticasone/salmeterol during the 12-week treatment period. The primary objective was to demonstrate non-inferiority of fluticasone/formoterol versus fluticasone/salmeterol, measured by pre-dose forced expiratory volume in the first second (FEV1), at week 12.
  
  
  RESULTS
  Fluticasone/formoterol was comparable to fluticasone/salmeterol for the primary efficacy endpoint, mean pre-dose FEV1 at week 12. The new combination was also comparable to fluticasone/salmeterol for change from baseline to week 12 in pre-dose FEV1, change from pre-dose FEV1 at baseline to 2-hour post-dose FEV1 at week 12 and discontinuations due to lack of efficacy. Importantly, fluticasone/formoterol was superior to fluticasone/salmeterol in time to onset of action throughout the duration of the study. The two treatments demonstrated similar results for various other secondary efficacy parameters, including other lung function tests, patient-reported outcomes, rescue medication use, asthma exacerbations and Asthma Quality of Life Questionnaire scores. Fluticasone/formoterol was well tolerated and had a good safety profile that was similar to fluticasone/salmeterol.
  
  
  CONCLUSIONS
  The results of this study indicate that fluticasone/formoterol is as effective as fluticasone/salmeterol, and has a more rapid onset of action, reflecting the faster bronchodilatory effects of formoterol compared with those of salmeterol. If patients perceive the benefits of therapy with fluticasone/formoterol more rapidly than with fluticasone/salmeterol, this could have a positive impact on preference and adherence.
authors: Department of Allergology and Internal Medicine, Medical University of Białystok, Białystok, Poland. abodzentalukaszyk@gmail.com
authors: Anna
authors: A
authors: Bodzenta-Lukaszyk
authors: Andrzej
authors: A
authors: Dymek
authors: Kirsten
authors: K
authors: McAulay
authors: Heikki
authors: H
authors: Mansikka
references: J Allergy Clin Immunol. 2007 Dec;120(6):1360-7
references: 17981317
references: Allergy. 2004 May;59(5):469-78
references: 15080825
references: Respiration. 2005;72 Suppl 1:6-12
references: 15915007
references: J Allergy Clin Immunol. 2002 Oct;110(4):603-6
references: 12373268
references: Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003534
references: 16034902
references: Am J Respir Crit Care Med. 1999 Jul;160(1):244-9
references: 10390407
references: Eur Respir J. 1999 May;13(5):988-92
references: 10414394
references: J Asthma. 2009 Nov;46(9):861-6
references: 19905909
references: Cochrane Database Syst Rev. 2007 Oct 17;(4):CD002310
references: 17943772
references: Curr Med Res Opin. 2009 Jun;25(6):1563-71
references: 19445651
references: Eur Respir J. 2007 Mar;29(3):587-95
references: 17329493
references: Int Arch Allergy Immunol. 2006;141(2):189-98
references: 16899987
references: Eur Respir J. 2004 Apr;23(4):559-64
references: 15083754
references: BMC Pulm Med. 2009 May 19;9:24
references: 19454036
references: Allergy Asthma Proc. 2009 Mar-Apr;30(2):139-47
references: 19463204
references: Respir Med. 2011 May;105(5):674-82
references: 21196104
references: J Investig Allergol Clin Immunol. 2010;20(1):9-12
references: 20232768
references: Am Rev Respir Dis. 1981 Jun;123(6):659-64
references: 7271065
references: Respir Med. 2009 Jan;103(1):41-9
references: 18977646
references: J Clin Epidemiol. 1993 Oct;46(10):1103-11
references: 8410095
references: J Asthma. 2008 Nov;45(9):723-9
references: 18972285
references: Eur Respir J. 1996 Apr;9(4):636-42
references: 8726924
references: J Asthma. 2004;41(8):797-806
references: 15641629
references: J Allergy Clin Immunol. 2004 Feb;113(2):245-51
references: 14767437
references: BMC Pulm Med. 2006 Jun 13;6:13
references: 16772035
references: Trials. 2009 Jun 03;10:37
references: 19493350
references: Curr Med Res Opin. 2007 Aug;23(8):1809-20
references: 17597557
references: J Clin Epidemiol. 2009 May;62(5):479-84
references: 18468856
references: Eur Respir Rev. 2010 Jun;19(116):150-7
references: 20956184